Open AccessEvaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
Author(s) -
Shashikant Srivastava,
Johanna Van Zyl,
Kayle Cirrincione,
Katherine Martin,
Tania A Thomas,
Devyani Deshpande,
J. W. C. Alffenaar,
James A Seddon,
Tawanda Gumbo
Publication year - 2020
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002857
Subject(s) - medicine , ceftriaxone , tuberculosis , surgery , microbiology and biotechnology , pathology , antibiotics , biology
Ceftazidime-avibactam is an effective agent for the treatment of tuberculosis (TB) but requires frequent administration because of a short half-life. Due to a longer half-life, ceftriaxone could allow intermittent dosing.